Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Panoptes Pharma

Panoptes Pharma?uq=AFYHfsyn
2013 FOUNDED
PRIVATE STATUS
1-10 EMPLOYEES
Seed LATEST DEAL TYPE
$1.07M LATEST DEAL AMOUNT
6 INVESTORS
Description

Provider of molecule based therapies intended to help in the treatment of severe eye diseases. The company's molecule based therapies focuses on a new treatment for autoimmune uveitis and adenoviral conjunctivitis and has therapeutic potential for additional inflammatory and viral indications, enabling users to get thier medical needs fulfilled.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Primary Office
  • Reisnerstraße 34/1
  • Vienna, 1030
  • Austria

+43 01 0000000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Panoptes Pharma’s full profile, request a free trial.

Panoptes Pharma Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Seed Round 02-Nov-2015 $1.07M 00.000 Completed Generating Revenue
3. Grant 00.000 00.00 Completed Generating Revenue
2. Seed Round 26-Sep-2013 $1.6M $1.6M Completed Generating Revenue
1. Accelerator/Incubator $37.3K Completed Generating Revenue
To view this company’s complete deal history including valuation and funding, request access »

Panoptes Pharma Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
4SC Corporation Minority 000 0000 000000 0
ARAX Capital Partners Venture Capital Minority 000 0000 000000 0
Austria Wirtschaftsservice Other Minority 000 0000 000000 0
aws Gründerfonds Venture Capital Minority 000 0000 000000 0
Life Science Austria Other Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »

Panoptes Pharma Executive Team (2)

Name Title Board
Seat
Contact
Info
Franz Obermayr Ph.D Co-Founder & Chief Executive Officer
Stefan Sperl Ph.D Co-Founder & Chief Operating Officer